British drugmaker Shire Plc said it would buy Dyax Corp for about $5.9 billion to gain access to the drug developer’s late-stage treatment for a severe breathing difficulty. The offer price of $37.30 per …
British drugmaker Shire Plc said it would buy Dyax Corp for about $5.9 billion to gain access to the drug developer’s late-stage treatment for a severe breathing difficulty. The offer price of $37.30 per …